ENMD-2076: Updated Phase II data

Updated data from a single-arm, open-label, North American Phase II trial in 57 evaluable patients showed that once-daily oral ENMD-2076 produced a 6-month PFS rate of 19%. There were 4 partial responses and 30 cases of stable disease. Median OS has not yet been reached. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...